Comparative Analysis of the Molecular Characteristics of Group B Streptococcus Isolates Collected from Pregnant Korean Women Using Whole-genome Sequencing

Yangsoon Lee, M.D., Ph.D.,1 Hye Gyung Bae, M.D., Ph.D.,2 Dongju Won, M.D., Ph.D.,3, Woobin Yun, M.S.,4 Hyukmin Lee, M.D., Ph.D.,3 Jong Rak Choi, M.D., Ph.D.,3, Young Uh, M.D., Ph.D.,5, and Kyungwon Lee, M.D., Ph.D.2,3

1Department of Laboratory Medicine, Hanyang University College of Medicine, Seoul, Korea; 2Seoul Clinical Laboratories, Yongin, Korea; 3Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea; 4Department of Laboratory Medicine, Graduate School of Medical Sciences, Brain, Korea 21 Project, Yonsei University College of Medicine, Seoul, Korea; 5Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea

Background: The incidence of early- and late-onset sepsis and meningitis in neonates due to maternal rectovaginal group B Streptococcus (GBS) colonization may differ with serotype distribution and clonal complex (CC). CC17 strains are associated with hypervirulence and poor disease outcomes. GBS serotypes are distinguished based on the polysaccharide capsule, the most important virulence factor. We determined the sequence type distribution of GBS isolates from pregnant women in Korea and validated whole-genome sequencing (WGS)-based prediction of antimicrobial susceptibility and capsular serotypes in GBS isolates.

Methods: Seventy-five GBS isolates collected from pregnant Korean women visiting Wonju Severance Christian Hospital, Wonju, Korea between 2017 and 2019 were subjected to WGS using the NovaSeq 6000 system (Illumina, San Diego, CA, USA). Multilocus sequence types, serotypes, antimicrobial resistance genes, and hemolysin operon mutations were determined by WGS, and the latter three were compared with the results of conventional phenotypic methods.

Results: The predominant lineage was CC1 (37.3%), followed by CC19 (32.0%), CC12 (17.3%), and CC17 (4.0%). All isolates were cps typeable (100%, (75/75), and 89.3% of cps genotypes (67/75) were concordant with serotypes obtained using latex agglutination. The cps genotypes of the 75 isolates were serotypes III (24.0%), V (22.7%), and VIII (17.3%). All isolates harboring intact ermB and tet were non-susceptible to erythromycin and tetracycline, respectively. Three non-hemolytic strains had 1-bp frameshift insertions in cylE.

Conclusions: The low prevalence of CC17 GBS colonization may explain the low frequency of neonatal GBS infections. WGS is a useful tool for simultaneous genotyping and antimicrobial resistance determination.

Key Words: Group B Streptococcus, Whole-genome sequencing, Serotype, Sepsis, Neonate
INTRODUCTION

Group B Streptococcus (GBS) is a critical pathogen that causes meningitis and sepsis in neonates. Neonatal GBS isolates are mainly acquired from the maternal genitourinary tract. The most important virulence factor of GBS is its polysaccharide capsule encoded by cps. Based on the capsule, 10 serotypes (Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX) with different disease-causing abilities are distinguished [1]. Serotypes and antimicrobial resistance profiles are important parameters for the characterization and treatment of invasive GBS infections [2]. Serotype III isolates belonging to clonal complex (CC) 17 are associated with hypervirulence and poor disease outcomes [3-5]. In a study in the Netherlands, most isolates obtained from neonates showing invasive infections were clustered into one of five major lineages: CC17 (39%), CC19 (25%), CC23 (18%), CC10 (9%), and CC1 (7%) [3]. The number of neonatal GBS infections caused by CC17 isolates has significantly increased [3, 4, 6]. In contrast, CC1, CC12, and CC23 are more common in pregnant women [6]. In Korea, the prevalence of GBS lineages has not yet been reported.

With the rapid advances in bioinformatics that have allowed analyzing and storing large amounts of whole-genome sequencing (WGS) data, it has become possible and feasible to obtain genetic information of bacteria in clinical microbiology laboratories. Recent studies have used WGS for molecular capsular typing and antimicrobial resistance gene typing of GBS [7-9]. As comprehensive data, including multilocus sequence types (MLSTs), serotypes, resistomes, and virulence factors, can be extracted from a single WGS dataset, WGS is a practical and economical method as compared with conventional phenotypic methods [9, 10].

We for the first time investigated the sequence type (ST) distribution of GBS isolates collected from pregnant women in Korea and validated WGS-based antimicrobial susceptibility and capsular serotypes of the GBS isolates.

MATERIALS AND METHODS

Bacterial collection and WGS

In total, 75 GBS isolates were collected from pregnant Korean women visiting Wonju Severance Christian Hospital, Korea between May 2017 and May 2019, as previously reported [11]. The study was approved by the Yonsei University Wonju Severance Christian Hospital Institutional Review Board (IRB No. CR319119). Sequencing libraries for all isolates were prepared using the Twist Library Preparation EF Kit (Twist Bioscience, San Francisco, CA, USA) according to the manufacturer’s instructions. Briefly, extracted DNA was assessed using the Qubit dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Fifty nanograms of high-quality DNA in 40 μL of 10 mM Tris-HCl (pH 8.0) was enzymatically fragmented, and DNA ends were repaired by dA-tailing in a C1000 Touch Thermal Cycler (Bio-Rad, Hercules, CA, USA). The dA-tailed DNA fragments were ligated with Twist Universal Adapters compatible with the NovaSeq 6000 system (Illumina, San Diego, CA, USA) at 20°C for 30 minutes. The ligated libraries were PCR-amplified in six cycles using Twist UDI primers in a thermal cycler. The quantities and size ranges of the final libraries were validated using the Qubit dsDNA BR Assay Kit (Thermo Fisher Scientific) and Agilent 4200 TapeStation System (Agilent Technologies, Santa Clara, CA, USA). All libraries were equally pooled, and the pooled library was diluted to 2 nM for sequencing, denatured in 0.2 N NaOH, and diluted with 400 mM Tris-HCl (pH 8.0) to 400 pmol/L. The diluted library was sequenced using paired-end (2×150 bp) sequencing on the NovaSeq 6000 system (Illumina). De novo assembly from the FASTAQ files generated after sequencing was performed using Unicycler (v0.4.0, https://github.com/rrwick/Unicycler). The median depth of coverage was 1,050×, with maximum depths of 2,264× to 529×.

Whole-genome analysis

The FASTA files generated after assembly were analyzed using tools provided on the Center for Genomic Epidemiology website (http://www.genomicepidemiology.org/) and the PubMLST database (http://pubmlst.org) to determine MLSTs, cps genotypes, antimicrobial resistance genes, and the hemolysin operon regions of the GBS isolates. The cps genotypes were analyzed using the cpsG-K region, as previously suggested [7, 8]. We compared the WGS-based serotypes, antimicrobial resistance genes, and phenotypic characteristics with the findings of a previous study that conducted antimicrobial susceptibility testing and serotyping of GBS isolates using the Strep-B-Latex kit (SSI Diagnostica, Hillerød, Denmark) [9].

Antimicrobial susceptibility test

Antimicrobial susceptibility was tested using the MicroScan MicroSTREP Plus Panel (Beckman Coulter, Brea, CA, USA), which covers ampicillin, penicillin, cefotaxime, ceftiraxone, cefepime, meropenem, levofloxacin, clindamycin, erythromycin, tetracycline, chloramphenicol, and vancomycin. GBS isolates showing inconsistent results between WGS and previous methods were
RESULTS

MLSTs of GBS isolates
The distribution of GBS isolates according to MLST CCs is shown in Table 1. The predominant CC was CC1 (N=28, 37.3%), followed by CC19 (N=24, 32.0%) and CC12 (N=13, 17.3%). CC1 was composed of ST1, ST2, ST667, and ST676, whereas CC19 was composed of ST19, ST27, ST335, and ST1911. Three isolates (4.0%) belonged to ST17—a hypervirulent strain. Two new STs (ST1911 and ST1912) were identified (Table 1).

Latex serotypes and cps genotypes
All isolates (100%, 75/75) were cps typeable, and 89.3% (67/75) of the cps genotypes were in agreement with serotypes determined using latex agglutination. Of the 16 isolates with discordant results, eight were confirmed by retesting using latex agglutination and WGS (Table 2). The cps genotypes of the 75 isolates mainly included serotypes III (N=18, 24.0%), V (N=17, 22.7%), and VIII (N=13, 17.3%). CC19 isolates were of serotype III.

Table 1. Distribution of MLST CCs and STs and cps genotypes among 75 GBS isolates collected from pregnant Korean women

| CC | ST | cps genotype |
|----|----|--------------|
|    |    | La | Ib | II | III | V  | VI | VII | VIII | Total |
| 1  | 2  | 13 |    |    | 13  |    |    |     |       |       |
|    | 1  | 6  | 3  | 1  | 10  |    |    |     |       |       |
|    | 676| 4  |    |    | 4   |    |    |     |       |       |
|    | 667|    | 1  |    | 1   |    |    |     |       |       |
| 19 | 19 | 5  | 8  |    | 13  |    |    |     |       |       |
|    | 335| 5  |    |    | 5   |    |    |     |       |       |
|    | 27 | 3  | 2  |    | 5   |    |    |     |       |       |
|    | 1911| 1 |    |    | 1   |    |    |     |       |       |
| 12 | 10 | 5  |    |    | 5   |    |    |     |       |       |
|    | 12 | 3  |    |    | 3   |    |    |     |       |       |
|    | 654| 3  |    |    | 3   |    |    |     |       |       |
|    | 8  | 1  |    |    | 1   |    |    |     |       |       |
|    | 1912| 1 |    |    | 1   |    |    |     |       |       |
| 23 | 23 | 4  |    |    | 4   |    |    |     |       |       |
| 17 | 17 | 3  |    |    | 3   |    |    |     |       |       |
| 22 | 22 | 1  |    |    | 1   |    |    |     |       |       |
| NA | 498|    | 1  |    | 1   |    |    |     |       |       |
| NA | 529|    |    | 1  | 1   |    |    |     |       |       |
| Total (%)| 4 (5.3) | 10 (13.3) | 8 (10.7) | 18 (24.0) | 17 (22.7) | 4 (5.3) | 1 (1.3) | 13 (17.3) | 75 |

Abbreviations: CC, clonal complex; ST, sequence type; MLST, multilocus ST; cps, capsular polysaccharide gene; GBS, group B Streptococcus; NA, not assigned.

Table 2. Retyping of isolates with discordant results between latex agglutination serotyping and cpsG-K genotyping

| Isolate | Latex agglutination serotype | cpsG-K genotype |
|---------|-----------------------------|-----------------|
| WJ1     | VII                         | VI              |
| WJ4     | VIII                        | III             |
| WJ10    | IX                          | IX              |
| WJ11    | la                          | V               |
| WJ12    | VII                         | V               |
| WJ14    | VIII                        | III             |
| WJ21    | IX                          | IX              |
| WJ36    | V                           | V               |
| WJ37    | V                           | V               |
| WJ41    | V                           | V               |
| WJ47    | IX                          | Ib              |
| WJ50    | VII                         | VII             |
| WJ59    | IX                          | Ib              |
| WJ60    | Ib, II                      | II              |
| WJ64    | Ib                          | Ib              |
| WJ68    | II                          | Ib              |

Abbreviation: cps, capsular polysaccharide gene.
| cps genotype (N isolates) | CC | ST | MIC (µg/mL) | Susceptibility | erm mutation | MIC (µg/mL) | Susceptibility | tet mutation |
|---------------------------|----|----|-------------|----------------|--------------|-------------|----------------|--------------|
| V (17)                    | 1  | 1  | 256         | R              | ermB         | ≥8          | R              | tetM         |
|                           | 1  | 1  | 256         | R              | ermB         | ≥8          | R              | tetM         |
|                           | 1  | 1  | 256         | R              | ermB         | ≥8          | R              | tetM         |
|                           | 19 | 19 | 256         | R              | ermB         | ≥8          | R              | tetM         |
|                           | 19 | 19 | 16          | R              | ermA         | ≥8          | R              | tetM         |
|                           | 0.12 | 19 | S           | ermA         | ≥8          | R              | tetM         |
|                           | 0.06 | 19 | S           | ermA         | ≥8          | R              | tetM         |
|                           | 0.25 | 19 | S           | -            | ≥8          | R              | tetM         |
|                           | 0.12 | 19 | S           | -            | ≥8          | R              | tetM         |
|                           | 0.06 | 19 | S           | -            | ≥8          | R              | tetM         |
|                           | 27  | 2  | R           | ermB         | ≥8          | R              | tetO         |
|                           | 2   | 2  | R           | ermB         | ≥8          | R              | tetO         |
|                           | NA  | 498 | 0.06       | S            | -            | ≥8          | R              | tetM         |
| III (18)                  | 19 | 19 | 256         | R              | ermB         | ≥8          | R              | tetM         |
|                           | 256 | 19 | R           | ermB         | ≥8          | R              | tetM         |
|                           | 0.50 | 19 | I           | ermB         | ≥8          | R              | tetM         |
|                           | 0.06 | 19 | S           | -            | ≥8          | R              | tetM         |
|                           | 0.06 | 27 | S           | -            | ≥8          | R              | tetM         |
|                           | 0.06 | 33 | S           | -            | ≥8          | R              | tetM         |
|                           | 256 | 5  | R           | ermB         | ≥8          | R              | tetM         |
|                           | 256 | 1  | R           | ermB         | ≥8          | R              | tetM         |
|                           | 1  | 1  | R           | ermB         | ≥8          | R              | tetM         |
|                           | 1   | 1  | R           | ermB         | ≥8          | R              | tetM         |
|                           | 0.06 | 1911 | S    | ermA   | ≥8          | R              | tetM         |
|                           | 0.06 | 529  | S     | -     | ≥8          | R              | tetO         |
|                           | 0.06 | 17  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 17  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.25 | 23  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 23  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 23  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 22  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 22  | S     | -     | ≥8          | R              | tetM         |
|                           | 0.06 | 22  | S     | -     | ≥8          | R              | tetM         |
|                           | 256 | 22  | R     | ermB   | ≥8          | R              | tetM         |

(Continued to the next page)
types III and V, whereas CC12 were of serotypes Ib and II. CC1 isolates were of diverse serotypes, including II, V, VI, VII, and VIII.

Antimicrobial susceptibility and antimicrobial resistance genes
Erythromycin resistance was predicted by the presence of erm, which encodes a methylase (Table 3). Twenty-nine isolates (38.7%) harbored erm, including 20 harboring ermB and nine harboring ermA. Eighteen isolates carrying intact ermB were non-susceptible to erythromycin, with 13 isolates showing high-level resistance (minimum inhibitory concentration [MIC] ≥128 μg/mL). One isolate with a premature termination codon (E128stop) in ermB and one isolate with a 15-bp insertion in ermB were susceptible to erythromycin. Among the nine isolates harboring ermA, six were resistant to erythromycin, whereas the remaining three were susceptible. Forty-seven isolates (62.7%) harbored tet, including 34 harboring tetM and 13 harboring tetO. Although the 46 isolates having intact tetM or tetO genes were resistant to tetracycline, one isolate was susceptible to tetracycline because of a premature termination codon in tetO (E203stop). No β-lactam-resistant isolate was identified.

Hemolysin operon analysis
Among the 75 isolates, six were non-hemolytic. We analyzed the cyl operon (12 kb) and abxI regulatory gene reported previously [12]. A 1-bp insertion in cylE at position 903/2,004 was detected in three non-hemolytic strains belonging to ST27. AbxI mutations were not found in any of the isolates.

DISCUSSION
CC1 and CC19 are among the major GBS CCs associated with invasive disease and colonization in humans [6, 13, 14]. CC1 is phylogenetically close to CC19 [6, 15]. We found that 69.3% of Korean pregnant women carried CC1 or CC19 GBS. CC17 GBS strains belong to a hypervirulent lineage of homogeneous serotype III clones and are associated with a disproportionately high frequency of invasive neonatal diseases, particularly, meningitis [3, 16]. In Korea, the prevalence of neonatal GBS cases is low [17, 18]. A multicenter study showed that 157 neonatal GBS cases were identified in 14 university hospitals of Korea between 1996 and 2005 [17]. Another study reported 10 GBS cases (0.3%) among 3,862 infants during 2010–2017 [18]. In this study, only three (4.0%) isolates were of CC17, and neonatal infection with maternal CC17 GBS was not observed. The low prevalence of CC17 GBS colonization may explain the low frequency of neonatal GBS infections.

Serotype classification of GBS is based on the capsular polysaccharide, of which 10 variants are known to exist. The capsular polysaccharide is encoded on the cps locus, which comprises 16–18 genes. Kapatai, et al. [7] have suggested that molecular serotypes based on the variable cpsG-K region demonstrated the best performance in terms of typeability and concordance with latex agglutination. Therefore, we compared phenotypic serotyping using latex agglutination with molecular genotyping using the cpsG-K region. All isolates (100%) were typeable by WGS-based cpsG-K genotyping, and 89.3% of the genotypes were concordant with latex agglutination results; isolates showing discordant results were retested. Similarly, Kapatai, et al. [7] reported a concordance rate of 86.7% in initial testing and of 98.2% in retesting between cps genotyping and latex agglutination results. However, one study has indicated that the determination of GBS serotypes is often hampered by poor capsule expression [19].

Serotypes Ia, Ib, II, III, and V account for 98% of the colonizing GBS isolates identified worldwide [5]. However, serotype distribution varies with geography and ethnicity. In the United States, Europe, and Australasia, serotypes Ia, II, III, and V account for

| cps genotype (N isolates) | CC | ST | MIC (µg/mL) | Susceptibility | erm mutation | MIC (µg/mL) | Susceptibility | tet mutation |
|----------------------------|----|----|-------------|----------------|--------------|-------------|----------------|--------------|
|                           |    |    |             |                |              |             |                |              |
| Ib (2)                    | 12 | 8  | 0.06        | S              | -            | ≥8          | R              | tetM         |
| VI (2)                    | 1  | 667| 128         | R              | ermB         | 0.5         | S              | tetO (E203*) |
|                           | 1  | 0.06| S          |              | ermB        | 0.5         | S              | -            |
| VII (1)                   | 1  | 1  | 0.06        | S              | -            | ≥8          | R              | tetM         |

*a Stop codon; † A 15-bp fragment inserted at position 238.

Abbreviations: ST, sequence type; cps, capsular polysaccharide gene; CC, clonal complex; S, susceptible; I, intermediate; R, resistant; MIC, minimum inhibitory concentration; NA, not assigned.
80%–90% of clinical isolates, whereas serotypes IV, VI, VII, VIII, and IX are relatively less frequent [5, 19]. Serotype III, which is associated with invasive disease, accounts for 25% worldwide; however, it is less frequent in South American (11%) and South-Eastern Asian (12%) populations [5]. Serotypes VI, VII, VIII, and IX are common in Asia [5]. Our results demonstrated that serotypes III and V are predominant in Korean pregnant women; they were found in 24.0% and 22.7% of the women, respectively, followed by serotype VIII (17.3%). These results suggest that continuous monitoring of serotype distribution is important in epidemiological and vaccine-related studies [19, 20]. Associations between STs and serotypes have been reported in the literature, with some studies reporting strong correlation and others very weak correlation [21, 22]. Ramaswamy, et al. [21] observed correlations between serotype III and ST17 and between Ib and ST12; serotype V was found to be present in all STs, except for ST17. Similarly, we found correlations between serotype III and ST17 and between serotype VIII and ST2.

We compared antimicrobial susceptibility results with antimicrobial resistance genes detected using WGS. Tetracycline resistance was predominantly caused by tetM and tetO, whereas macrolide resistance was predominantly due to the presence of erm, with ermB being more prevalent. In a previous study, resistant and intermediate-resistant GBS isolates showed high frequencies of tetM (97.6%) and low frequencies of tetO (2.4%), ermB (34.5%), and ermTR (10.3%) [23]. In this study, 45.3% harbored tetM, 17.3% harbored tetO, 26.7% harbored ermB, and 12.0% harbored ermA. Isolates carrying intact tetM or tetO were predicted to be resistant to tetracycline. Regarding erythromycin resistance, our results are similar to those reported by Mingoia, et al. [24], in which ermB and ermA were associated with high-level and variable-level erythromycin resistance, respectively. Multidrug resistance to erythromycin, clindamycin, and tetracycline, coupled with the recovery of non-susceptible isolates resistant to antimicrobial agents such as cefazolin, penicillin G, and ampicillins indicates the importance of GBS surveillance and antimicrobial susceptibility testing [23].

Mutations are localized predominantly in the cyl operon, encoding the β-hemolytic pigment biosynthetic pathway, and in abx1, encoding a CovSR regulatory partner [12]. In the present study, three non-hemolytic strains (WJ16, WJ29, and WJ46) had 1-bp frameshift insertions at nucleotide 903 of cylE. However, abx1 mutations were not found.

This study had some limitations. First, our results are not representative of all pregnant Korean women, as we used single-center data. Second, we collected the isolates from pregnant women, not from neonates, and the strains involved in GBS infection in these two groups are not necessarily the same.

In conclusion, CC1 and CC19 GBS are prevalent in pregnant Korean women. The low prevalence of CC17 GBS, which mainly causes neonatal invasive infection, explains the low frequency of neonatal GBS infections in Korea. WGS data can predict the serotypes of GBS isolates based on cps genotypes. Detection of tetM and tetO and ermB is predictive of resistance to tetracycline and erythromycin, respectively. Therefore, WGS is a useful tool for simultaneous genotyping and antimicrobial resistance determination.

ACKNOWLEDGEMENTS

None.

AUTHOR CONTRIBUTIONS

Lee K and Uh Y designed the study; Uh Y, Bae HG, Won D, Yun W, Choi JK, and Lee H collected and identified clinical isolates and performed molecular studies; Lee Y analyzed the data; Lee Y, Lee K, and Uh Y wrote, edited, and reviewed the manuscript. All authors revised and accepted the final version of the manuscript.

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article are reported.

RESEARCH FUNDING

This study was supported by a research grant from Seoul Clinical Laboratories.

ORCID

Yangsoo Lee https://orcid.org/0000-0003-3821-3741
Hye Gyung Bae https://orcid.org/0000-0003-3821-3741
Dongju Won https://orcid.org/0000-0001-6399-9091
Woobin Yun https://orcid.org/0000-0002-0084-0216
Hyukmin Lee https://orcid.org/0000-0001-8785-7207
Jong Rak Choi https://orcid.org/0000-0002-8523-4126
Young Uh https://orcid.org/0000-0002-0608-2989
Kyungwon Lee https://orcid.org/0000-0002-8797-8780

https://doi.org/10.3343/alm.2023.43.2.180
REFERENCES

1. Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of the art. Ther Adv Vaccines 2015;3:76-90.
2. Kardos S, Tóthpál A, Laub K, Kristóf K, Ostorházi E, Rozgonyi F, et al. High prevalence of group B streptococcus ST17 hypervirulent clone among non-pregnant patients from a Hungarian venereology clinic. BMC Infect Dis 2019;19:1009.
3. Jamroz D, Bijlsma MW, de Goffau MC, van de Beek D, Kuijpers TW, Parkhill J, et al. Increasing incidence of group B Streptococcus neonatal infections in the Netherlands is associated with clonal expansion of CC17 and CC23. Sci Rep 2020;10:9539.
4. Hsu JF, Tsai MH, Lin LC, Chu SM, Lai MY, Huang HR, et al. Genomic characterization of nonhemolytic and nonpigmented group B streptococci resistant to macrolides. J Clin Microbiol 2016;54:1388-90.
5. Russell NJ, Seale AC, O’Driscoll M, O’Sullivan C, Bianchi-Jassir F, Gonzalez-Guarrin J, et al. Maternal colonization with group B Streptococcus and serotype distribution worldwide: systematic review and meta-analyses. Clin Infect Dis 2017;65(S2):S100-11.
6. Manning SD, Springman AC, Lehtozky E, Lewis MA, Whittam TS, Davies HD. Multilocus sequence types associated with neonatal group B streptococcal sepsis and meningitis in Canada. J Clin Microbiol 2009;47:1143-8.
7. Kapatai G, Patel D, Efstratiou A, Chalker VJ. Comparison of molecular serotyping approaches of Streptococcus agalactiae from genomic sequences. BMC Genomics 2017;18:429.
8. Sheppard AE, Vaughan A, Jones N, Turner P, Turner C, Efstratiou A, et al. Capsular typing method for Streptococcus agalactiae using whole-genome sequence data. J Clin Microbiol 2016;54:1388-90.
9. Metcalf BJ, Chochua S, Gertz RE, Jr., Hawkins PA, Ricardi J, Li Z, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive Streptococcus agalactiae recovered in the USA. Clin Microbiol Infect 2017;23:574.e7-8.
10. Shin H, Takahashi T, Lee S, Choi EH, Maeda T, Fukushima Y, et al. Comparing genomic characteristics of Streptococcus pyogenes associated with invasiveness over a 20-year period in Korea. Ann Lab Med 2022;42:438-46.
11. Choi SJ, Kang J, Uh Y. Recent epidemiological changes in Group B Streptococcus among pregnant Korean women. Ann Lab Med 2021;41:380-5.
12. Six A, Firon A, Plainvert C, Caplain C, Bouaboud A, Touak G, et al. Molecular characterization of nonhemolytic and nonpigmented group B streptococci responsible for human invasive infections. J Clin Microbiol 2016;54:75-82.
13. Diedrick MJ, Flores AE, Hillier SL, Creti R, Ferrieri P. Clonal analysis of colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States. J Clin Microbiol 2010;48:3100-4.
14. Lin HC, Chen CJ, Chang KH, Yen TY, Ho CM, Hwang KP, et al. Clonal dissemination of invasive and colonizing clonal complex 1 of serotype VI group B Streptococcus in central Taiwan. J Microbiol Immunol Infect 2016;49:902-9.
15. Furfaro LL, Chang BJ, Payne MS. Perinatal Streptococcus agalactiae epidemiology and surveillance targets. Clin Microbiol Rev 2018;31:e00049-18.
16. Nagaoka K, Konno S, Murase K, Kikuchi T, Nakagawa I. Complete genome sequence of Streptococcus agalactiae serotype III, multilocus sequence type 335 strain HU-65823, isolated from a human patient in Japan with severe invasive infection. Microbiol Resour Announc 2018;7:e01303-18.
17. Park KH, Kim KH, Kang JH, Kim KN, Kim DS, Kim YK, et al. Current status and clinical presentations of invasive neonatal Group B streptococcal infections in Korea. Pediatr Int 2011;53:236-9.
18. Kim SJ, Kim GE, Park JH, Lee SL, Kim CS. Clinical features and prognostic factors of early-onset sepsis: a 7.5-year experience in one neonatal intensive care unit. Korean J Pediatr 2019;62:36-41.
19. Kong F, Lambertsen LM, Skotved HC, Ko D, Wang H, Gilbert GL. Use of phenotypic and molecular serotype identification methods to characterize previously nonserotypeable group B streptococci. J Clin Microbiol 2008;46:2745-50.
20. Paoletti LC and Madoff LC. Vaccines to prevent neonatal GBS infection. Semin Neonatol 2002;7:315-23.
21. Ramaswamy SV, Ferrieri P, Flores AE, Paoletti LC. Molecular characterization of nontypeable group B Streptococcus. J Clin Microbiol 2006;44:2398-403.
22. Morozumi M,Wajima T, Kuwata Y, Chiba N, Sunaoshi K, Sugita K, et al. Associations between capsular type, multilocus sequence type, and macrolide resistance in Streptococcus agalactiae isolates from Japanese infants with invasive infections. Epidemiol Infect 2014;142:812-9.
23. Mudzana R, Maventyewa RT, Gudzha-Mugabe M. Analysis of virulence factors and antibiotic resistance genes in group B Streptococcus from clinical samples. BMC Infect Dis 2021;21:125.
24. Mingoia M, Morici E, Marini E, Brenciani A, Giovanetti E, Varaldo PE, et al. Macrolide resistance gene erm(TR) and erm(TR)-carrying genetic elements in Streptococcus agalactiae: characterization of ICesagTR7, a new composite element containing IMEsPl2907. J Antimicrob Chemother 2016;71:593-600.